Enrolling by invitationPhase 2NCT06926621

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Studying Steinert myotonic dystrophy

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Vertex Pharmaceuticals Incorporated
Intervention: VX-670(drug)
Enrollment: 44 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2029

Study locations (11)

Wesley Research Institute, Auchenflower, Australia
Neuroscience Clinical Trials Unit, Alfred Brain, Melbourne, Australia
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology, Leuven, Belgium
Altasciences Montreal, Montreal, Canada
Montreal Neurological Institute-Hospital, Montreal, Canada
University of Ottawa, Ottawa, Canada
Universite Laval - Neurology, Québec, Canada
Hospital Universitario y Politecnico La Fe - Neurology, Valencia, Spain
Queen Elizabeth University Hospital - Neurology, Glasgow, United Kingdom
Leonard Wolfson Experimental Neurology Centre CRF, London, United Kingdom
Royal Hallamshire Hospital - Neurology, Sheffield, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06926621 on ClinicalTrials.gov

Other trials for Steinert myotonic dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Steinert myotonic dystrophy →

← Back to all trials